Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). The firm is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The firm's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The firm's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.
Follow-Up Questions
GLMD hissesinin fiyat performansı nasıl?
GLMD 'in mevcut fiyatı $1.49 'dir, son işlem günde 1.12% decreased etti.
Galmed Pharmaceuticals Ltd için ana iş temaları veya sektörler nelerdir?
Galmed Pharmaceuticals Ltd Biotechnology endüstrisine ait ve sektör Health Care 'dir
Wall Street analistlerine göre, 3 analist Galmed Pharmaceuticals Ltd için analist derecelendirmeleri gerçekleştirdi, bunlar 0 güçlü al, 0 al, 3 tut, 1 sat ve 0 güçlü sat içermektedir
